CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Emgality 120 MG in 1 ML Prefilled Syringedrug
Likely dose
Emgality 120 MG in 1 ML Prefilled Syringefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04271202
NCT04271202Phase 4Completed
CompareCT.gov

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Beth Israel Deaconess Medical Center·interventional·Posted Feb 17, 2020·Updated Mar 24, 2026

In Brief

A Phase 4 clinical trial evaluating Emgality 120 MG in 1 ML Prefilled Syringe for Chronic Migraine. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention. Specifically, the protocol will allow the investigators to determine whether the main site of action of this novel and recently-approved class of migraine prophylactic drugs act inside or outside the brain and if so, where.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedFeb 17, 2020
Enrollment StartJul 29, 2020
Primary CompletionNov 22, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.4 years ago

Interventions

Emgality 120 MG in 1 ML Prefilled Syringedrug

Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.